Clinical trials: Gastrointestinal Reflux
Non-erosive Reflux Disease, Erosive Esophagitis
A Study to Evaluate the Long-Term Safety of BLI5100 in Patients With Gastroesophageal Reflux Disease
The objective of this study is to evaluate the safety of up to 12 months (52 weeks) of once daily oral administration of BLI5100 in patients with non-erosive reflux disease (NERD) or healed erosive esophagitis (EE).
- Trial name
- NCT05890001
- Testing
- BLI5100
- Where
- 60 sites in United States
- Volunteers
- 400 people
- Sponsor
- Braintree Laboratories
Gastroparesis
Domperidone for Refractory Gastrointestinal Disorders
The purpose of this study is to prescribe oral domperidone for subjects with gastrointestinal disorders who have failed or suffered adverse effects from standard medical treatment.
- Trial name
- NCT00777439
- Testing
- Domperidone
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Arnold, George, M.D.
Non-erosive Reflux Disease
A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Non-Erosive Reflux Disease
The objective of the Treatment Phase of the study is to evaluate the safety and efficacy of 4 weeks of once daily oral administration of BLI5100 low dose, BLI5100 high dose, or placebo in patients with NERD.
- Trial name
- NCT05587322
- Testing
- BLI5100
- Where
- 112 sites in United States
- Volunteers
- 788 people
- Sponsor
- Braintree Laboratories
Symptomatic Non-erosive Gastroesophageal Reflux Disease
A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Through 24 Weeks
The main objective is to assess the efficacy of vonoprazan (10 mg as needed) compared to placebo (as needed) in relief of episodic heartburn at 2 hours that is sustained for 24 hours over 12 weeks of treatment in participants…
- Trial name
- NCT07752407
- Testing
- Vonoprazan
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Phathom Pharmaceuticals, Inc.
Leg Ulcer, Veins, Varicose
Effect of PEM Treatment of Superficial Axial and Tributary Vein Reflux on Improvement of Wound Healing in VLUs
This study evaluates the addition of polidocanol endovenous microfoam (PEM) to compression therapy to determine effectiveness in improving the healing of venous leg ulcers (VLUs) in adults with severe venous disease of the great…
- Conditions
- Leg Ulcer, Veins, Varicose, Venous Ulcer, Reflux
- Trial name
- NCT02988063
- Testing
- Polidocanol Endovenous Microfoam (PEM)
- Where
- United States
- Sponsor
- OhioHealth
Gastroesophageal Reflux Disease (GERD), Chronic Laryngitis
Salivary Epidermal Growth Factor (EGF) Concentration Before and After Treatment of Reflux Laryngitis
Saliva plays a key role in the homeostasis of the digestive tract The reflux of gastroesophageal contents may cause damage to the esophageal, laryngeal and pharyngeal mucosas There seems to be no correlation between the severity…
- Trial name
- NCT01389401
- Testing
- omeprazole
- Where
- Brazil
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Faculdade de Ciências Médicas da Santa Casa de São Paulo
GERD
STRETTA ,Radio Frequency Ablation (RFA) v/s Sham Therapy for the Treatment of Refractory GERD
Gastro-esophageal reflux disease (GERD) is a chronic disorder with significant impact on the quality of life of patients. It may also lead to several complications like peptic strictures, ulcerations, Barrett 's disease and…
- Trial name
- STRETTAGERD (NCT02935881)
- Testing
- Radio Frequency Ablation (RFA) (Stretta Procedure)
- Where
- India
- Volunteers
- 20 people
- Sponsor
- Asian Institute of Gastroenterology, India
Non-erosive Reflux Disease
Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Non Erosive Reflux Disease
The purpose of this study is to demonstrate the superiority of efficacy of CJ-12420, once daily (QD), compared to placebo in patients with non-erosive reflux disease at Week 4
- Trial name
- NCT02556021
- Testing
- CJ-12420 50mg, CJ-12420 100mg
- Where
- South Korea
- Volunteers
- 324 people
- Sponsor
- HK inno.N Corporation
Acute Coronary Syndrome, Myocardial Infarction
Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)
The purpose of the COGENT-1 clinical trial is to determine whether CGT-2168 (clopidogrel and omeprazole) compared to clopidogrel is safe and effective in reducing the incidence of gastrointestinal bleeding and symptomatic ulcer…
- Conditions
- Acute Coronary Syndrome, Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
- Trial name
- COGENT-1 (NCT00557921)
- Testing
- CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin, Plavix (clopidogrel 75 mg) and aspirin
- Where
- 491 sites in United States, Australia and 14 more
- Volunteers
- 5,000 people
- Sponsor
- Cogentus Pharmaceuticals
Barrett's Esophagus
Detection of Barrett s Esophagus in Patients Without GERD Symptoms
The purpose of this study is to develop a method to detect Barrett's esophagus (BE) in individuals with a new office-based diagnostic test.
- Trial name
- NCT04880044
- Testing
- EsoCheck/EsoGuard (EC/EG), Esophago-gastro-duodenoscopy (EGD)
- Where
- United States
- Volunteers
- 132 people
- Sponsor
- Case Comprehensive Cancer Center
Gastroesophageal Reflux Disease
Esomeprazole in PPI Failures - IMPROVE
The purpose of this study is to assess how PPI treated GERD patients with insufficient symptom control will benefit from a change in management by providing a more efficient acid secretion inhibition during 4 weeks, by evaluation…
- Trial name
- NCT00272701
- Testing
- Esomeprazole, Other PPI marketed in Sweden
- Where
- 42 sites in Sweden
- Volunteers
- 450 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease, Morbid Obesity
Gastroesophageal Reflux Disease (GERD) Before and After Gastric Bypass
The hypothesis of this study was that gastric bypass (GBP) ameliorates gastroesophageal reflux disease (GERD) in morbidly obese patients.
- Trial name
- NCT00951093
- Testing
- Gastric bypass
- Where
- Brazil
- Volunteers
- 53 people
- Sponsor
- Clinica Gastrobese
Gastro Esophageal Reflux
Antireflux Ablation Therapy (ARAT) for Gastroesophageal Reflux Treatment
Gastroesophageal Reflux Disease (GERD) is defined as the rise of gastric or gastroduodenal contents above the esophagogastric junction (EGJ), generating symptoms and/or esophageal lesions.
- Trial name
- ARAT (NCT03548298)
- Testing
- ARAT
- Where
- Mexico
- Volunteers
- 95 people
- Sponsor
- Coordinación de Investigación en Salud, Mexico
Reflux Esophagitis, Hiatal Hernia
Immunologic Factors in Reflux Esophagitis and Barrett's Esophagus
By using combination of the expression of COX-2 and NOS and immunologic reaction in the esophagus with manometry of LES and cruel diaphragm and 24 hr esophageal pH monitoring to investigate the mechanisms and to make a new and…
- Trial name
- NCT00155805
- Where
- Taiwan
- Volunteers
- 90 people
- Sponsor
- National Taiwan University Hospital
Asthma, Gastroesophageal Reflux Disease
Evaluate the Effects on Asthma Control of Rabeprazole Given Twice Daily in Subjects With Asthma.
The hypothesis for this study is that potent anti-secretory therapy with high dose PPI improves asthma control regardless of either asthma severity or the presence of GERD symptoms.
- Trial name
- NCT00214552
- Testing
- rabeprazole
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Associated Scientists to Help Minimize Allergies
Gastroesophageal Reflux, Heartburn
A Study of Efficacy and Safety of "On-demand" Maintenance Therapy With Rabeprazole in Patients With Non-erosive Reflux Disease (NERD)
The purpose of this study is to assess the efficacy and safety of long-term, "on-demand" maintenance therapy with rabeprazole in patients with non-erosive reflux disease (NERD).
- Trial name
- NCT00236392
- Testing
- rabeprazole
- Volunteers
- 422 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Gastroesophageal Reflux Disease, Reflux, Gastroesophageal
A Study To Investigate The Effectiveness Of AH234844 (Lavoltidine) Compared With NEXIUM And Ranitidine.
Current treatment for gastroesophageal reflux disease (GERD) confirms an unmet need in patients, based on slow onset of action and an inability to provide 24-hour gastric-acid suppression.
- Trial name
- NCT00405119
- Testing
- AH23844 (lavoltidine), NEXIUM (esomeprazole), ZANTAC (ranitidine)
- Where
- 2 sites in Australia
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Tricuspid Regurgitation
Percutaneous Treatment of Tricuspid Valve Regurgitation With the TriCinch System™
The TriCinch System™ is intended for percutaneous treatment of tricuspid regurgitation. It is a percutaneous catheter-based device designed for tricuspid valve repair in order to decrease effective cross-sectional area and…
- Trial name
- PREVENT (NCT02098200)
- Testing
- TriCinch System
- Where
- 14 sites in France, Germany and 2 more
- Volunteers
- 24 people
- Sponsor
- 4Tech Cardio Ltd.
Venous Insufficiency
Investigation of the Transmission Pathways of Reflux in Patients With Chronic Venous Insufficiency
Chronic venous insufficiency (CVI) is one of the most common medical problems in adults that occurs secondary to the reflux of blood through incompetent valves of lower extremity veins.
- Trial name
- NCT06369207
- Where
- Iran
- Volunteers
- 50 people
- Sponsor
- Golestan University of Medical sciences
Gastro-esophageal Reflux Disease, Functional Dyspepsia
Relationship Between Gastric Accommodation, TLESRs and Reflux in HV and in GERD With or Without Overlapping Dyspepsia
Our group recently studied the relationship between intra-gastric pressure (IGP) and reflux events after a meal, both in gastro-esophageal reflux disease (GERD) and in healthy volunteers (HV).
- Conditions
- Gastro-esophageal Reflux Disease, Functional Dyspepsia, Health
- Trial name
- NCT03788109
- Testing
- device: combined solid state HRiM
- Where
- Belgium
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.